PP_1170x120_10-25-21

Reflect (Study 304)

Eisai and Merck announce FDA approval of Lenvima

Eisai and Merck announce FDA approval of Lenvima

WOODCLIFF LAKE, N.J. and KENILWORTH, N.J. – Eisai Inc. and Merck, known as MSD outside of the United States and Canada, announced  that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from Reflect (Study 304),

Adheris Health